On April 17, 2013, the Personalized Medicine Coalition (PMC) and Biotechnology Industry Organization (BIO) are convening the first of the “PMC/BIO Solutions Summits” in Washington, D.C. to ensure that personalized medicine is recognized as a key part of the healthcare system.  To begin moving the needle on personalized medicine, the summit will bring key stakeholders together to identify methods for encouraging and improving patient access to novel molecular diagnostic products.

The dialogue around solutions to advance personalized medicine will be important to many key stakeholders in the healthcare community.  To allow for greater participation by stakeholders, we are providing the following involvement opportunities for the first PMC/BIO Solutions Summit.  To learn more about these unique sponsorship packages, please contact Mary Bordoni at 202-589-0070 or mbordoni@PersonalizedMedicineCoalition.org.  We look forward to your participation.

Platinum Sponsorship, $25,000

• Logo and name on summit signage and promotional materials
• Quote and logo on summit webpage
• Full-page advertisement and logo in onsite program
• Onsite tabletop exhibit space
• Opportunity to introduce featured panel and/or speaker, depending on availability
• Verbal acknowledgement during summit introduction
• 3 complimentary registrations, 2 discounted registrations

Gold Sponsorship, $15,000

• Logo and name on summit signage and promotional materials
• Quote and logo on summit webpage
• Half-page advertisement and logo in onsite program
• Onsite tabletop exhibit space
• Verbal acknowledgement during summit introduction
• 2 complimentary registrations, 1 discounted registration

Silver Sponsorship, $10,000

• Logo and name on summit signage and promotional materials
• Quote and logo on summit webpage
• Quarter-page advertisement and logo in onsite program
• Verbal acknowledgement during summit introduction
• 1 complimentary registration, 1 discounted registration

Bronze Sponsorship, $5,000

• Logo on event summit signage and promotional materials
• Logo on summit webpage and in onsite program
• Verbal acknowledgement during summit introduction
• 1 complimentary registration

Personalized medicine will change the way medicine is practiced.  Patients will benefit from new therapies while experiencing fewer side effects and; physicians will be armed with more precise tools; and medicine will be practiced in a more efficient and effective manner.  Further, this greater precision in treatment will reshape drug and biologic development, dramatically advance our understanding of the pathogenesis of disease, eliminate waste from our healthcare system, and improve the overall quality and efficiency of care.  However, the policy challenges are daunting, and it will take cooperation among all stakeholders to bring these benefits to fruition. 

Though personalized medicine holds the potential to be a game changer in patient care, none of this promise will be realized unless there are adequate business models to support product development.  Currently, economic and regulatory disincentives are impeding the development of novel molecular diagnostic products.  The strength of patents in this area is too uncertain, the regulatory environment is too fractured, and the reimbursement system lacks adequate specificity and certainty to stimulate robust business investment.  Given these conditions, payers, healthcare providers and patients have yet to collaborate to determine how to best capitalize on the benefits available to them.  The Personalized Medicine Coalition (PMC) and the Biotechnology Industry Organization (BIO) are committed to bringing stakeholders together to eliminate these barriers to innovation and encourage patient access, in order to ensure that our healthcare system benefits from all personalized medicine promises to offer. 

To answer these challenges, PMC and BIO have partnered to create a series of “PMC/BIO Solutions Summits” to convene stakeholders with the charge to discuss potential solutions to these important barriers.  In the first of this series, the summit discussions will help articulate:

• Opportunities to streamline the personalized medicine research and development process through payer collaboration.
• The infeasibility of large scale randomized controlled clinical trials and the challenges of subject recruitment and return on investment for testing personalized medicine diagnostics. 
• Alternative models for meeting evidentiary standards in patient populations or indications where randomized controlled clinical trials are not feasible.
• Payer concerns regarding and the depth of clinical data adequate to meet those requirements.
• Gaps in education around the value of personalized medicine diagnostics to payers, patients and healthcare providers.
• Strategies and tactics for the demonstration of healthcare cost savings from adoption of personalized medicine diagnostics, and for inclusion of personalized medicine diagnostics in physician practice guidelines.
• Challenges, recent changes and improvements needed in the current payment system for novel molecular diagnostics.
• Potential approaches to incentivize industry in the development of innovative personalized medicine diagnostics (e.g., patent reforms, regulatory exclusivity models, and changes to the reimbursement system).
• Mechanisms to include patients and physicians in the discussion about coverage and reimbursement that often play out without input from these important stakeholders.

The Personalized Medicine Coalition

The Personalized Medicine Coalition (PMC), representing scientists, patients, providers and payers, promotes the understanding and adoption of personalized medicine concepts, services and products to benefit patients and the health system.

Through its members, PMC seeks to:

• Provide opinion leadership on public policy issues that affect personalized medicine;
• Help educate the public, policymakers, government officials and private sector health care leaders about the public and personal health benefits of personalized medicine;
• Serve as a forum for identifying and informing others of those public policies that may impede the ability to deliver the promise of personalized medicine; and
• Create a structure for achieving consensus positions on crucial public policy issues and supporting changes needed to further the public interest in personalized medicine.

The Biotechnology Industry Organization

The Biotechnology Industry Organization (BIO) is the world’s largest biotechnology trade association. BIO is a 501(c)(6) non-profit organization headquartered in Washington, D.C. that provides advocacy, business development, and communications services for more than 1,100 members worldwide. Its mission to be the champion of biotechnology and the advocate for its member organizations - both large and small.

BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. They work to improve the human condition by curing the sick, feeding the hungry or developing cleaner, safer and healthier sources of energy.

The Omni Shoreham Hotel welcomes attendees of the BIO and PMC Joint Summit. To reserve a room and receive the special conference rate simply click on the link below, or call 1-800-THE-OMNI and ask for the “BIO and PMC Joint Summit Room Block or the group code: 12400612072.

Book a hotel room

Please note that guest reservations must be in by Monday, March 25 in order to secure the group rate of $269. For those in the area, please see our driving directions.

View Larger Map

The Omni Shoreham Hotel provides valet parking only, for $33 per day with in-and-out privileges.

The nearest metro stop is Woodley Park along the Red Line. The hotel is approximately a ten-minute walk from the metro. For walking directions from the Woodley Park station, please see below: